DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

Patients were randomly assigned to calorie restriction with dapagliflozin 10 mg/day or placebo ... The study was partially ...

The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...

Dapagliflozin (Farxiga, AstraZeneca) received approval based ... insulin or both were randomly assigned to 5 mg or 10 mg dapagliflozin, 2.5 mg or 5 mg saxagliptin, or placebo as an add-on ...

Lupin has received tentative approval from the Food and Drug Administration for Dapagliflozin and Saxagliptin Tablets, 5 mg/5 mg and 10 mg/5 mg, which is the generic of AstraZeneca’s Qtern.

After that, Heerspink's group only continued with part B of the trial: zibotentan 1.5 mg plus dapagliflozin 10 mg/day and zibotentan ... The trial was funded by AstraZeneca. Some co-authors ...

for high dose (1.5 mg zibotentan / 10 mg dapagliflozin; n=179) and –27.0% (90% CI –38.4 to –13.6; p=0.002) for low dose (0.25 mg / 10 mg; n=91). The percentage mean change from baseline in ...

dapagliflozin (10 mg) alone, taken daily over 12 weeks. Key endpoints include change from baseline in UACR at week 12 and fluid retention throughout the trial. AstraZeneca in CVRM Cardiovascular ...